FRSX
Foresight Autonomous Holdings Ltd.
There isn't enough reported data to score FRSX yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
FRSX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
FRSX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
FRSX PE Valuation
FRSX has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
FRSX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| High |
Analysts expect FRSX's losses to grow, with revenue declining.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
FRSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.50 | +$0.35 |
| Q4 2024 | -$0.50 | +$0.76 |
| Q2 2024 | -$0.85 | +$3.50 |
| Q4 2023 | -$1.26 | +$7.20 |
| Q2 2023 | -$4.35 | +$3.33 |
| Q4 2022 | -$8.46 | -$3.00 |
| Q2 2022 | -$7.68 | -$1.38 |
| Q4 2021 | -$5.46 | +$3.36 |
FRSX has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
FRSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $158K | -25% |
| Q2 2025 | $240K | +7.1% |
| Q4 2024 | $212K | -52% |
| Q2 2024 | $224K | +307% |
| Q4 2023 | $442K | +46% |
| Q2 2023 | $55K | -78% |
FRSX's revenue has slid since its 2023 peak: $158,000 last quarter, down 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -3789% | -2138 points |
| Q2 2025 | -2581% | +13775 points |
| Q4 2024 | -3097% | -172 points |
| Q2 2024 | -2728% | +749 points |
| Q4 2023 | -1650% | N/A |
| Q2 2023 | -16356% | N/A |
| Q4 2022 | -2925% | N/A |
| Q2 2022 | -3476% | N/A |
FRSX's operating margin was −3789% last quarter, down 2138 points from the same quarter a year ago.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over FRSX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
FRSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.1M | +$859K |
| Q2 2025 | -$5.4M | -$220K |
| Q4 2024 | -$6M | +$1M |
| Q2 2024 | -$5.2M | +$2.9M |
| Q4 2021 | -$6.5M | -$776K |
| Q2 2021 | -$5.8M | -$39K |
| Q4 2020 | -$5.8M | +$460K |
| Q2 2020 | -$5.8M | -$41K |
FRSX has burned cash in almost every quarter: −$22M over the past year, against −$27M the year before.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
FRSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +5.1M shares |
| 1 year | +968% | +24.8M shares |
FRSX has 27M diluted shares, up 968% from a year ago.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over FRSX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
FRSX Net Leverage
FRSX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
FRSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.9 | Oversold |
| Stochastic | 6.7 | Oversold |
FRSX's weekly RSI is 21 (oversold) and its Stochastic is 7 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
FRSX PE vs Consumer Cyclical Sector
FRSX has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
FRSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.82 | 30% below |
| 20 week MA | $1.12 | 49% below |
| 50 week MA | $2.16 | 74% below |
| 100 week MA | $7.77 | 93% below |
| 200 week MA | $21.1 | 97% below |
FRSX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
FRSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $132.3 | $632.5 | +378% |
| 2021 | $632.5 | $235.6 | -63% |
| 2022 | $235.6 | $64.3 | -73% |
| 2023 | $64.3 | $21.6 | -66% |
| 2024 | $21.6 | $38.6 | +79% |
| 2025 | $38.6 | $4.50 | -88% |
| 2026 YTD | $4.50 | $0.57 | -87% |
FRSX's yearly returns have swung widely, from +378% in 2020 to −88% in 2025. It's down 87% so far in 2026.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over FRSX on returns for 2026, with the stronger performance.